-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Celecoxib + Ciprofloxacin) in Alzheimer’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Celecoxib + Ciprofloxacin) in Alzheimer's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Celecoxib + Ciprofloxacin) in Alzheimer's Disease Drug Details: PrimeC is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AVB-001 in Metastatic Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AVB-001 in Metastatic Ovarian Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AVB-001 in Metastatic Ovarian Cancer Drug Details: AVB-001 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – StabiliC in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - StabiliC in Parkinson's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.StabiliC in Parkinson's DiseaseDrug Details:StabiliC is a fixed dose combination of celecoxib and...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Celecoxib + Ciprofloxacin) in Amyotrophic Lateral Sclerosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Celecoxib + Ciprofloxacin) in Amyotrophic Lateral Sclerosis report and make more profitable business decisions. How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ERAS-601 in Non-Small Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. ERAS-601 in Non-Small Cell Lung Cancer Drug Details: ERAS-601 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ABBV-368 in Oral Cavity (Mouth) Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ABBV-368 in Oral Cavity (Mouth) Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.ABBV-368 in Oral Cavity (Mouth) CancerDrug Details:ABBV-368 is under development for...
-
Product Insights
NewNeuroWave Systems Inc Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our NeuroWave Systems Inc Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. NeuroWave Systems Inc (NeuroWave) is a medical device company. It develops and commercializes brain monitors with electrodes. The company offers various products such as neurosense monitor and easyprep electrodes. Its NeuroSENSE monitor is a bilateral brain monitor, which measure anesthetic effects on the brain and respond instantaneously to changes in patient state. NeuroWave's EasyPrep electrodes is a proprietary disposable...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – (celecoxib + ciprofloxacin)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry (celecoxib + ciprofloxacin) Drug Details PrimeC is a fixed dose combination drug of celecoxib...
-
Product Insights
Amyotrophic Lateral Sclerosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The symptoms of amyotrophic lateral sclerosis include difficulty breathing, difficulty swallowing, head drop due to weakness of the neck muscles, muscle cramps, speech problems, such as a slow or abnormal speech pattern (slurring of words), voice changes, hoarseness, weight loss. The Amyotrophic Lateral Sclerosis pipeline market research report provides comprehensive information on the therapeutics under development for Amyotrophic Lateral Sclerosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type....
-
Product Insights
Parkinson’s Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Parkinson's disease (PD) is a neurodegenerative disorder characterized by movement dysfunctions. The main finding in brains of people with PD is loss of dopaminergic neurons in substantia nigra. Symptoms generally develop slowly over years. People with PD experience dyskinesia, dystonia, tremor, stiffness and impaired locomotory functions. Risk factors include age, genetic factors, environmental factors and gender. Treatment options include anticholinergics, COMT inhibitors and dopamine agonists. The Parkinson’s disease pipeline drugs market research report provides comprehensive information on the therapeutics under...